---
title: "Four‑drug Mass Drug Administration with IDA and Azithromycin Reduces Lymphatic Filariasis, Scabies"
id: "medrxiv-19-impact-of-mass-drug-administration-of-ivermectin-diethylcarbamazine-albendazole"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-19-impact-of-mass-drug-administration-of-ivermectin-diethylcarbamazine-albendazole"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.07.30.26359257v1?rss=1"
published_at: "2026-08-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Four‑drug Mass Drug Administration with IDA and Azithromycin Reduces Lymphatic Filariasis, Scabies
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-19-impact-of-mass-drug-administration-of-ivermectin-diethylcarbamazine-albendazole
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.07.30.26359257v1?rss=1)
- **Published At:** 2026-08-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- A four‑drug **mass drug administration (MDA)** combining **ivermectin**, diethylcarbamazine, albendazole (IDA) and **azithromycin** was delivered in West New Britain Province (WNBP), Papua New Guinea. The intervention is the first reported use of this combined regimen in the province. - Baseline surveys sampled 3,552 participants across 43 villages selected using model‑based geostatistics. Active surveillance included circulating filarial antigen (CFA) testing, microfilaria (Mf) microscopy, and skin examinations for scabies and yaws‑like lesions. - Pre‑MDA prevalence: CFA positive 151/3,552 (4.3%), Mf positive 49/3,552 (1.4%), scabies 489/3,552 (13.8%), and yaws‑like lesions 130/3,552 (3.6%). - Repeat surveys in 10 high‑burden villages one year after MDA showed substantial declines: **CFA** positivity fell 49% (RR 0.51; 95% CI 0.38–0.70; p<0.0001; from 11.5% to 5.9%), **Mf** prevalence fell 85% (RR 0.15; 95% CI 0.07–0.30; p<0.001; 4.7% to 0.9%), **scabies** fell 78% (RR 0.22; 95% CI 0.14–0.33; p<0.0001; 11.1% to 2.4%), and yaws‑like lesions decreased 31% (RR 0.69; 95% CI 0.41–1.14; p=0.15; 3.8% to 2.5%). - Passive surveillance used electronic data from 27 health centres comparing monthly attendances six months before versus after MDA. Monthly attendances for yaws‑like lesions decreased (mean 27.4 ± 0.9 to 15.5 ± 1.6; p<0.0001) and for other skin diseases decreased (95.6 ± 3.4 to 72.9 ± 7.7; p<0.0001). Total non‑skin disease attendances did not change significantly. - The study reports that MDA with **IDA and azithromycin** reduced community burden of **lymphatic filariasis** and skin infections in WNBP and demonstrates the value of combined active and passive surveillance to monitor impact. - Ethical approvals were obtained from the Papua New Guinea Medical Research Council and Case Western Reserve University IRB; data are available on request. Funders included Takeda Pharmaceuticals and the Australian NHMRC (RG204078).
## Clinical Analysis & Structured Key Points
Impact of Mass Drug Administration of Ivermectin, Diethylcarbamazine, Albendazole, and Azithromycin on Lymphatic Filariasis, Scabies, and Yaws in West New Britain Province, Papua New Guinea | medRxiv Skip to main content Impact of Mass Drug Administration of Ivermectin, Diethylcarbamazine, Albendazole, and Azithromycin on Lymphatic Filariasis, Scabies, and Yaws in West New Britain Province, Papua New Guinea Simon Westby , Jocelyn Salo , Joseph Nale , Wendy Hoiunei , Jastina Kakul , Michael Payne , Catherine Bjerum , Rose N. Mauyet , Nozomu Aoki , Masato Yamauchi , Susana Vaz Nery , Margaret Baker , Julie Jacobson , View ORCID Profile Emmanuele Giorgi , Moses Laman , Christopher L. King doi: https://doi.org/10.64898/2026.07.30.26359257 Simon Westby 1 Papua New Guinea Institute of Medical Research; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: simon.westby2{at}nhs.net Jocelyn Salo 2 Papua New Guinea Institute for Medical Research; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Joseph Nale 3 West New Britain Provincial Health Authority; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Wendy Hoiunei 4 National Department of Health, Papua New Guinea; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jastina Kakul 3 West New Britain Provincial Health Authority; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Michael Payne 5 Case Western Reserve University School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Catherine Bjerum 5 Case Western Reserve University School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rose N. Mauyet 6 Japan International Cooperation Agency; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nozomu Aoki 6 Japan International Cooperation Agency; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Masato Yamauchi 6 Japan International Cooperation Agency; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Susana Vaz Nery 7 University of New South Wales; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Margaret Baker 8 Georgetown University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Julie Jacobson 9 Bridges to Development; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Emmanuele Giorgi 10 Lancaster University Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Emmanuele Giorgi Moses Laman 1 Papua New Guinea Institute of Medical Research; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christopher L. King 5 Case Western Reserve University School of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract West New Britain province (WNBP), Papua New Guinea, is the first to combine ivermectin, diethylcarbamazine, albendazole (IDA), and azithromycin for mass drug administration (MDA). We describe the impact of four-drug MDA on lymphatic filariasis (LF), scabies, and yaws through active and passive surveillance. At baseline, 43 villages were surveyed following selection using model-based geostatistics. Repeat surveys were conducted in 10 high burden villages, one year after MDA. Circulating filarial antigen (CFA) and microfilaria (Mf) microscopy detected LF infections; skin examinations identified yaws and scabies. Electronic data from 27 health centers (HCs) compared monthly attendances in the six months before/after MDA. Pre-MDA, 151/3,552 (4.3%) participants tested CFA-positive, with 49 (1.4%) Mf-positive. Scabies was identified in 489/3,552 (13.8%) and yaws-like lesions in 130/3,552 (3.6%). In the 10 villages surveyed pre- and post-MDA, CFA positivity decreased by 49% (RR 0.51; CI 0.38, 0.70; p<0.0001; 11.5% to 5.9%), Mf prevalence 85% (RR 0.15; CI 0.07, 0.30; p<0.001; 4.7% to 0.9%), scabies 78% (RR 0.22; CI 0.14 - 0.33; p<0.0001; 11.1% to 2.4%) and yaws 31% (RR 0.69; CI 0.41 - 1.14; p=0.15; 3.8% to 2.5%). Mean (SEM) monthly HC attendances for yaws-like lesions decreased from 27.4 ± 0.9 to 15.5 ± 1.6 (p<0.0001) and for other skin diseases from 95.6 ± 3.4 to 72.9 ± 7.7 (p<0.0001), with no significant change in total non-skin disease attendances (728.8 ± 30.9 to 796.8 ± 44.4, p=0.178). MDA with IDA and azithromycin reduced LF and other skin infections burden in WNBP, demonstrating the effectiveness of four-drug MDA and the potential for using active and passive surveillance to monitor impact. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study received ethical approval for the protocol 'Applied Research for the Integrated Control and Elimination of Neglected Tropical Diseases in Papua New Guinea' from the PNG Medical Research Council (MRAC 22.17) and the Case Western Reserve University Institutional Review Board (STUDY20220661). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability All data produced in the present study are available upon reasonable request to the authors Funder Information Declared Takeda Pharmaceuticals Australian National Health and Medical Research Council , RG204078 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted August 02, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Impact of Mass Drug Administration of Ivermectin, Diethylcarbamazine, Albendazole, and Azithromycin on Lymphatic Filariasis, Scabies, and Yaws in West New Britain Province, Papua New Guinea Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Impact of Mass Drug Administration of Ivermectin, Diethylcarbamazine, Albendazole, and Azithromycin on Lymphatic Filariasis, Scabies, and Yaws in West New Britain Province, Papua New Guinea Simon Westby , Jocelyn Salo , Joseph Nale , Wendy Hoiunei , Jastina Kakul , Michael Payne , Catherine Bjerum , Rose N. Mauyet , Nozomu Aoki , Masato Yamauchi , Susana Vaz Nery , Margaret Baker , Julie Jacobson , Emmanuele Giorgi , Moses Laman , Christopher L. King medRxiv 2026.07.30.26359257; doi: https://doi.org/10.64898/2026.07.30.26359257 Share This Article: Copy Citation Tools Impact of Mass Drug Administration of Ivermectin, Diethylcarbamazine, Albendazole, and Azithromycin on Lymphatic Filariasis, Scabies, and Yaws in West New Britain Province, Papua New Guinea Simon Westby , Jocelyn Salo , Joseph Nale , Wendy Hoiunei , Jastina Kakul , Michael Payne , Catherine Bjerum , Rose N. Mauyet , Nozomu Aoki , Masato Yamauchi , Susana Vaz Nery , Margaret Baker , Julie Jacobson , Emmanuele Giorgi , Moses Laman , Christopher L. King medRxiv 2026.07.30.26359257; doi: https://doi.org/10.64898/2026.07.30.26359257 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (594) Allergy and Immunology (887) Anesthesia (322) Cardiovascular Medicine (4677) Dentistry and Oral Medicine (465) Dermatology (402) Emergency Medicine (631) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1593) Epidemiology (15643) Forensic Medicine (32) Gastroenterology (1176) Genetic and Genomic Medicine (6874) Geriatric Medicine (714) Health Economics (1034) Health Informatics (4847) Health Policy (1411) Health Systems and Quality Improvement (1699) Hematology (568) HIV/AIDS (1303) Infectious Diseases (except HIV/AIDS) (16145) Intensive Care and Critical Care Medicine (1143) Medical Education (650) Medical Ethics (148) Nephrology (703) Neurology (7022) Nursing (357) Nutrition (1056) Obstetrics and Gynecology (1206) Occupational and Environmental Health (987) Oncology (3509) Ophthalmology (1014) Orthopedics (381) Otolaryngology (432) Pain Medicine (453) Palliative Medicine (135) Pathology (695) Pediatrics (1752) Pharmacology and Therapeutics (724) Primary Care Research (750) Psychiatry and Clinical Psychology (5719) Public and Global Health (9546) Radiology and Imaging (2322) Rehabilitation Medicine and Physical Therapy (1406) Respiratory Medicine (1227) Rheumatology (628) Sexual and Reproductive Health (756) Sports Medicine (567) Surgery (750) Toxicology (105) Transplantation (298) Urology (278)
## Related Clinical Research

- [Genomic epidemiology and emerging antimicrobial resistance in Salmonella Paratyphi A from Australi](https://medichelpline.com/clinical-feed/medrxiv-13-genomic-epidemiology-and-emerging-antimicrobial-resistance-profiles-of.md)
- [Post-stroke recrudescence vs new stroke: distinguishing features, causes, investigations, and mana](https://medichelpline.com/clinical-feed/cmaj-2-a-58-year-old-patient-with-right-sided-weakness-and-a-history-of-stroke-practice.md)
- [Smartphone motor sequencing as scalable digital biomarkers of cognitive-motor function in CNS diso](https://medichelpline.com/clinical-feed/medrxiv-5-decomposing-cognitive-motor-planning-from-execution-smartphone-motor-sequencing.md)
- [Extracellular microRNAs in serum and EVs as candidate biomarkers for Chlamydia trachomatis reinfec](https://medichelpline.com/clinical-feed/plos-one-15-evaluation-of-extracellular-micrornas-as-potential-biomarker-candidates-for.md)
- [Azithromycin versus doxycycline with beta-lactams for hospitalised community-acquired pneumonia: t](https://medichelpline.com/clinical-feed/bmj-open-4-azithromycin-versus-doxycycline-in-hospitalised-adult-patients-with-community.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.